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Atrial fibrillation (AF) is a heritable disease that affects more than thirty million individuals worldwide. 
Extensive efforts have been devoted to the study of genetic determinants of AF. The objective of our 
study is to examine the effect of gene-gene interaction on AF susceptibility. We performed a large-scale 
association analysis of gene-gene interactions with AF in 8,173 AF cases, and 65,237 AF-free referents 
collected from 15 studies for discovery. We examined putative interactions between genome-wide SNPs 
and 17 known AF-related SNPs. The top interactions were then tested for association in an independent 
cohort for replication, which included more than 2,363 AF cases and 114,746 AF-free referents. One 
interaction, between rs7164883 at the HCN4 locus and rs4980345 at the SLC28A1 locus, was found to 
be significantly associated with AF in the discovery cohorts (interaction OR = 1.44, 95% CI: 1.27–1.65, 
P = 4.3 × 10–8). Eight additional gene-gene interactions were also marginally significant (P < 5 × 10–7). 
However, none of the top interactions were replicated. In summary, we did not find significant 
interactions that were associated with AF susceptibility. Future increases in sample size and denser 
genotyping might facilitate the identification of gene-gene interactions associated with AF.
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Atrial fibrillation (AF) is the most common cardiac arrhythmia, estimated to affect about 33.5 million individ-
uals globally1. The heritability of AF, particularly lone AF, has long been established2–8. Over the past few years, 
genome-wide association studies (GWAS) have successfully identified more than a dozen genetic loci associated 
with AF susceptibility9–14. These loci include genes involved in cardiac signaling, cardiopulmonary development, 
and regulation of atrial action potential duration. However, all together, these loci still explain less than 5% of the 
heritability of AF15, whereas a large proportion of heritability remains unknown16,17.
Epistasis refers to the interaction of multiple genes that might pose joint genetic effects. Epistasis plays a 
ubiquitous role in disease predisposition, conferring an increased risk in addition to the main effects for many 
complex diseases, such as breast cancer18 and coronary heart disease19. Gene-gene interactions play important 
roles in regulating various biological events and cellular behaviors20,21. However, it remains unclear whether gene 
interactions contribute to the biological basis of AF.
The most straightforward approach to identifying interactions is to perform an exhaustive search of all the 
possible combinations of genetic variants and to test if any of them are significantly associated with AF. However, 
a major problem with such a comprehensive search is the huge computational burden. Assuming one million 
SNPs are genotyped in a typical GWAS, a complete search of a two-marker model would require testing 5 × 1011 
pairs of SNPs. This number would further increase exponentially for multiple-SNP models. The cost of multi-
ple testing corrections even in the 1 million marker scenario is extreme. For example, a Bonferroni correction 
requires P < 1 × 10−13 for significance in such a number of tests. As few SNP pairs will meet this threshold, false 
negatives are likely without massive sample sizes.
It has been suggested that at least one variant in significant gene-gene interactions tends to have a strong main 
effect22. We therefore sought to identify potential interactions between top AF susceptibility SNPs and other 
genome-wide variants in relation to AF by performing a meta-analysis of results from multiple studies.
Results
In total, our study included 8,173 AF cases and 65,237 AF-free referents of European ancestry from 15 studies. 
The clinical characteristics of the study participants are shown in Table 1.
Supplemental Figure 1 presents Q-Q plots for the interaction p-values of genome-wide SNPs with each of 
the AF-associated variants. The effect of population stratification was negligible, with genomic control λ ranging 
from 0.98 to 1.01.
Table 2 shows the most significant interactions (P < 5 × 10−7) that were associated with AF susceptibility. The 
top 10 interactions for each AF SNP are shown in Supplemental Table 1. None of interactions reached the signif-
icance after adjusting for multiple testing (P < 5 × 10−8/17 = 2.8 × 10−9). Only one interaction, SNP rs7164883 
with rs4980345 exceeded the traditional genome-wide significance threshold (P < 5 × 10−8) for association 
with AF (P = 4.3 × 10−8). Both interacting SNPs are located in chromosome 15, 12Mb apart. The correspond-
ing regional plot is shown in Fig. 1, and the forest plot of each contributing study is shown in Fig. 2. The SNP 
rs7164883 is located within the first intron of HCN4, and was also one of the top SNPs found to be significantly 
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associated with AF in our previous study10. The SNP rs4980345 was located within the tenth intron of SLC28A1. 
SNP rs4980345 was not associated with AF (P = 0.78) in marginal analyses from the prior meta-analysis10.
As shown in Table 2, eight additional interactions also showed suggestive association with AF (P < 5 × 10−7). 
These interactions included two each with rs12415501 (NEURL), rs3807989 (CAV1), and rs1448818 (PITX2). 
There was one marginally significant interaction each with rs10821415 (C9orf3) and rs2106261 (ZFHX3).
We also tested the association of rs2106261 at the ZFHX3 locus and rs2200733 at the PITX2 locus with AF, 
which was recently reported to be associated with AF in a meta-analysis of three Chinese samples (OR = 5.36, 
P = 8.0 × 10−24)23. The interaction, however, was not significant in any of the 16 studies included in the present 
paper, or in our meta-analysis (all with P > 0.05).
We then tried to replicate our findings in an independent cohort, UK Biobank, which included more than 
2000 AF cases and 11,000 AF-free referents. As shown in Table 2, none of significant interactions from discovery 
phase were replicated (all with P > 0.05/9 = 0.0056).
Discussion
In the past decade, increasing evidence has suggested that the genetic predisposition is an important factor that 
contributes to AF as well as many other cardiovascular diseases24,25. Due to the enormous number of association 
tests, few studies have been performed to investigate the associations of gene interactions with AF susceptibility. 
By restricting our analyses to interactions with known AF loci, we limited the multiple testing burden in our 
analysis and sought to examine the potential mechanisms by which variants at top loci contribute to AF sus-
ceptibility. One genome-wide significant gene interaction with AF, rs7164883 at the HCN4 locus and rs4980345 
at the SLC28A1 locus, was found. Eight additional interactions were also marginally significant (P < 5 × 10−7), 
but did not withstand multiple testing correction. However, none of the top interactions were significant in the 
replication phase. It is noteworthy that the ORs of suggestive interactions from the replication cohort were very 
Study Group n Age, years Men, % HTN, % BMI, kg/m2 Diabetes, % MI, % CHF, %
Discovery
AFNET/KORA
Cases 448 51.0 ± 7.6 68 41 28.1 ± 5.2 8 1 2
Referents 438 55.8 ± 7.3 50 45 27.7± 4.3 4 0 1
AGES
Cases 399 78.6± 5.6 58 90 27.2 ± 4.4 13 6 9
Referents 2,560 76.1± 5.4 36 78 27.0 ± 4.5 11 5 1
ARIC
Cases 1,420 56.8 ± 5.4 57 41 28.2 ± 5.3 13 9 8
Referents 7,633 53.8 ± 5.6 45 24 26.8 ± 4.7 8 3 3
CCF
Cases 496 58.8 ± 10.7 76 58 30.2 ± 6.2 6 0 8
Referents 2,971 28.4 ± 22.2 38 – – – – –
CHS
Cases 1,011 72.7 ± 5.4 44 62 26.4 ± 4.5 14 0 0
Referents 2,190 72.0 ± 5.3 36 52 26.2 ± 4.4 11 0 0
FHS
Cases 956 71.9 ± 12.3 57 68 28.3 ± 5.5 13 9 3
Referents 7,470 51.8 ± 15.7 44 31 27.2 ± 5.3 5 2 1
HealthABC
Cases 129 74.4 ± 2.9 63 87 26.3 ± 3.9 – –
Referents 1,532 73.7 ± 2.8 52 62 26.6 ± 4.1 – –
LURIC
Cases 361 66.4 ± 27.7 72 75 27.7 ± 4.2 45 33 30
Referents 2,598 62.2 ± 10.7 70 73 27.4 ± 4.0 40 44 18
MGH/MIGEN
Cases 366 53.4 ± 10.5 81 23 27.8 ± 5.0 3 1 3
Referents 911 47.9 ± 8.8 53 – – – – –
PREVEND
Cases 272 61.3 ± 9.4 67 68 27.7 ± 4.4 7 12 3
Referents 3,277 48.4 ± 12.1 50 34 26.0 ± 4.2 4 2 0.1
PROSPER
Cases 505 76.0 ± 3.5 58 64 27.1 ± 4.3 11 19 0
Referents 4,739 75.3 ± 3.3 47 62 26.8 ± 4.2 10 13 0
RS-I
Cases 954 72.6 ± 8.5 46 65 26.7 ± 3.7 17 11 14
Referents 4,691 68.3 ± 8.8 40 53 26.2 ± 3.6 9 6 7
RS-II
Cases 146 71.5 ± 9.7 54 78 27.2 ± 4.3 22 12 6
Referents 2,011 64.3 ± 7.6 45 59 27.2 ± 4.2 12 4 1
SHIP
Cases 106 62.0 ± 10.3 63 55 29.6 ± 5.1 23 13 27
Referents 1,815 49.0 ± 14.4 47 24 27.2 ± 4.5 11 3 9
WGHS
Cases 959 58.2 ± 7.6 — 40 27.2 ± 5.3 5 — —
Referents 19,897 53.9 ± 4.9 — 23 25.8 ± 4.9 2 — —
Replication UK Biobank
Cases 2,363 62.3 ± 5.8 70 52 29.1  ± 5.5 13 13 12
Referents 114,746 56.7 ± 7.9 47 21 27.5 ± 4.8 5 2 0
Table 1.  Clinical characteristics of the participating studies. HTN – hypertension, defined as systolic blood 
pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg, or antihypertensive treatment. BMI – body mass 
index; Diabetes – diabetes mellitus; MI – myocardial infarction; CHF – heart failure. “− ” Signifies data not 
available.
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moderate. The most significant interaction from the discovery cohorts, rs7164883 with rs4980345, was even in 
the reverse direction in the replication cohort. Given that the replication cohort has similar genetic background 
to the discovery cohorts, the discrepancy indicates that these suggestive interactions are unlikely to be true 
AF-related interactions.
Our analyses were restricted to interactions with loci previously found to have a main effect association with 
AF. The underlying assumption of our approach is that interactions with significant effects tend to have observ-
able main effects in at least one of the interacting SNPs22. However, it is possible that two variants without main 
effects might have large interaction effects. Our analysis will not identify such interactions. A variety of other 
methods have been developed to account for the enormous number of interactions between variants in genetic 
association studies26,27. One approach is to employ prior biological knowledge to limit the search space28. Gene 
interactions have been discovered through experimental assays. These might be used to guide the search of poten-
tial variant interactions. Additionally, it has been recognized that many known genetic interactions were enriched 
with well-studied pathways, and could only happen under certain conditions29, which might introduce additional 
bias to the analysis. In fact, none of the top interactions identified in the present study was reported in known 
interaction databases30, suggesting that the interaction between some variants may arise through some other 
intermediate pathway.
We did not detect a recently reported interaction with AF by Huang and colleagues23. This interaction involved 
rs2106261 at the ZFHX3 locus and rs2200733 at the PITX2 locus. SNP rs2106261 was the most significant SNP at 
the ZFHX3 locus associated with AF in our earlier meta-analysis9. SNP rs2200733 was one of the top SNPs at the 
PITX2 locus, and is in complete linkage disequilibrium (r2 = 1.0) with the most significant SNP rs6817105, the 
SNP we tested in this study. One possible explanation for the discrepancy between the findings of the two studies 
is the difference in allele frequency between the Asian population studied by Huang23 vs. the European ances-
try population we studied (18% vs 28% for rs2106261, and 45% vs 16% for rs2200733, respectively). The effect 
of allelic difference and linkage disequilibrium could be amplified when the interaction was tested, suggesting 
that population stratification should be considered when comparing the results from studies based on different 
ethnicities.
We acknowledge several limitations of our study. All study participants in our study are of European ancestry, 
thus it is unclear whether our findings are relevant for populations of other ancestries. Furthermore, our analysis 
was restricted to two-variant interactions. However, it is possible that some interactions might involve more than 
two variants. Although our current study included more than 8,000 AF cases and 65,000 referents, it is possible 
that we did not have sufficient power to identify meaningful interactions for AF. We are currently expanding 
our AFGen Consortium to include additional cohorts, not only participants of European ancestry, but also par-
ticipants of African ancestry and Asian ancestry. With the increasing sample size, we might be able to identify 
significant interactions in the future. In addition, we are currently imputing genotypes from individual studies 
to emerging reference panels such as the Haplotype Reference Consortium31, which is expected to provide better 
resolution to identify interacting variants. Given that our current study only tested interactions with known AF 
Figure 1. Regional plot of the interaction between rs7164883 and SNPs close to rs4980345. Each dot 
represents one SNP. The x-axis represents the chromosomal position, whereas the y-axis represents the  
− log10(P) of the association of the interaction between rs7164883 and each SNP with AF.
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loci, we are also planning to expand our analyses to all interactions with the increasing sample size and more 
advanced computational methods.
In summary, we identified one genome-wide significant gene-gene interaction that was associated with AF 
susceptibility, suggesting that gene interactions might be involved in the development of AF. However, the finding 
was not replicated. Future work in functional genomics and efficient algorithms for epistasis analysis will likely 
facilitate the discovery of additional novel and high-order interactions that contribute to AF.
Materials and Methods
Study participants. Our discovery phase included individuals of European ancestry from 15 studies. These 
studies included the German Competence Network for Atrial Fibrillation/Cooperative Research in the Region 
of Augsburg (AFNET/KORA), Age, Gene/Environment Susceptibility Study (AGES) Reykjavik, Atherosclerosis 
Risk in Communities study (ARIC), Cleveland Clinic Lone AF GeneBank Study (CCAF), Cardiovascular Health 
Study (CHS), Framingham Heart Study (FHS), Health, Aging and Body Composition Study (HealthABC), 
Ludwigshafen Risk and Cardiovascular Health Study (LURIC), Massachusetts General Hospital Atrial Fibrillation 
Study (MGH), Prevention of Renal and Vascular Endstage Disease Study (PREVEND), the PROspective Study of 
Pravastatin in the Elderly at Risk study (PROSPER), Rotterdam Study (RS-I, RS-II), Study of Health in Pomerania 
AF SNP Interacting SNP Interaction effects Replication
SNP
Closest 
gene SNP Locus Closest gene Location
Coding 
allele CAF$
Meta P 
value OR+ 95% CI* P value OR+ 95% CI* P value
rs7164883 HCN4 rs4980345 15q25.3 SLC28A1 Intron T 0.06 0.78 1.44 1.27–1.65 4.3 × 10−8 0.94 0.74–1.20 0.64
rs10821415 C9orf3 rs1492056 3p14.1 MITF Intergenic A 0.43 0.37 1.15 1.09–1.21 1.4 × 10−7 0.91 0.84–0.99 0.04
rs12415501 NEURL rs699801 1p31.1 CRYZ Intergenic T 0.45 0.83 1.19 1.12–1.27 1.9 × 10−7 1.01 0.90–1.13 0.91
rs2106261 ZFHX3 rs12652090 5q34 TENM2 Intergenic A 0.11 0.43 1.31 1.18–1.45 2.1 × 10−7 1.02 0.87–1.20 0.80
rs1448818 PITX2 (2) rs693832 8p21.1 MIR3622B Intergenic C 0.11 0.36 1.27 1.16–1.39 3.1 × 10−7 1.03 0.89–1.19 0.72
rs3807989 CAV1 rs3802477 9q22.33 GABBR2 Intron C 0.05 0.30 1.35 1.20–1.52 3.6 × 10−7 1.05 0.86–1.27 0.64
rs3807989 CAV1 rs2327995 6p22.3 ATXN1 Intron G 0.27 0.74 1.15 1.09–1.22 4.3 × 10−7 1.05 0.95–1.15 0.32
rs1448818 PITX2 (2) rs2328452 20p11.23 RIN2 Intergenic G 0.88 0.92 1.25 1.15–1.37 4.7 × 10−7 0.94 0.82–1.08 0.37
rs12415501 NEURL rs7946907 11p15.2 SPON1 Intron A 0.54 0.05 1.18 1.11–1.26 4.7 × 10−7 1.07 0.96–1.20 0.23
Table 2.  Most significant interactions associated with AF (P < 5 × 10−7). $CAF: coding allele frequency; 
+OR: odds ratio; *CI: confidence interval.
Figure 2. Forest plot of the association of interaction between rs7164883 and rs4980345 with AF in each 
study. Each line represents the 95% confidence interval, and the size is proportional to the number of cases. OR: 
odds ratio.
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(SHIP), and Women’s Genome Health Study (WGHS). The replication phase was performed on UK Biobank. 
The study protocol was approved by the internal review boards of Ludwig Maximilian University of Munich, 
University of Iceland, University of Minnesota, Cleveland Clinic, University of Washington, Boston University 
Medical Campus, Wake Forest School of Medicine, Heidelberg University, Massachusetts General Hospital, 
University Medical Center Groningen, Leiden University Medical Center, Erasmus MC - University Medical 
Center Rotterdam, University Medicine Greifswald, and Brigham and Women’s Hospital. The study was per-
formed in accordance with the approved guidelines. All participants provided written informed consent to par-
ticipate in genetic research.
AF ascertainment. Details about AF ascertainment were described in previous publications9,10,14. Briefly, 
at each study, we combined evidence from a variety of sources to determine AF status, including electrocardio-
grams, Holter recordings, rhythm cards, medical records, and/or hospital discharge diagnostic codes. To achieve 
higher statistical power, we did not distinguish prevalent and incident AF cases, but combined them as individ-
uals with a history of AF.
Genotyping. Genotyping was performed independently in each study, using either Affymetrix SNP arrays or 
Illumina SNP arrays9, and then imputed to ~2.5 million SNPs in the HapMap II release 22 CEU panel to obtain 
a comprehensive set of SNPs across the genome. Detailed information regarding genotyping platforms, quality 
control metrics, and imputation methods for each study has been described previously9,10,12–14.
Known AF-associated variants. The known AF-associated variants were selected from recent GWAS 
meta-analysis results9,10,14. Ellinor et al. reported nine AF loci in the meta-analysis of AF9. Sinner et al. reported 
five additional loci that were marginally significant in the earlier analysis but became genome-wide signif-
icant when combining with additional studies10. Lubitz et al. performed conditional analysis on the known 
PITX2 locus14, and identified three additional independent SNPs within the locus. This resulted in a total of 17 
AF-associated SNPs with genome-wide significance. The SNPs included one top SNP at each AF locus, and three 
additional independent SNPs at the PITX2 locus. The full list of 17 SNPs is shown in Table 3.
Statistical Analyses. A multivariable logistic regression model was used to test the associations of interact-
ing SNPs with AF. Each interaction was comprised of one of the 17 AF SNPs, and one SNP from the ~2.5 million 
imputed HapMap Phase II SNPs. We assumed a multiplicative interaction effect as follows:
= β + β + β + β + β + β + β ∗age sexlog(odds AF) PCs SNP SNP SNP SNP0 age sex PCs 1 TopAF 2 2 int TopAF 2
in which β 1 and β 2 are the main effects for the known AF SNP and the SNP to be tested, respectively. β int represents 
the effect of the interaction between the AF SNP and the SNP to be tested. PCs represent principal components 
as necessary in each study to account for population structure. The model was also adjusted for age at DNA draw 
and sex, two factors that contribute significantly to AF risk. Studies with multiple study centers also adjusted for 
site. In order to account for the family correlation in FHS, we used generalized estimating equations (GEE) as 
implemented in the “geepack” R package. The association of each interaction with AF was adjusted for the inde-
pendence working correlation structure in FHS, where each pedigree was a cluster in the robust variance estimate 
for the effect of interest.
AF SNP
Closest 
Gene Locus
Coding 
allele
Non-coding 
allele
Coding allele 
frequency Source
rs6666258 KCNN3 1q21.3 C G 0.3 13
rs3903239 PRRX1 1q24.2 G A 0.45 9
rs4642101 CAND2 3p25.1 T G 0.28 10
rs1448818 PITX2 (2) 4q25 C A 0.17 14
rs6817105 PITX2 (1) 4q25 C T 0.12 9,11
rs4400058 PITX2 (3) 4q25 A G 0.12 14
rs6838973 PITX2 (4) 4q25 T C 0.47 14
rs13216675 GJA1 6q22.31 C T 0.27 10
rs3807989 CAV1 7q31.2 A G 0.44 9
rs10821415 C9orf3 9q22.32 A C 0.40 9
rs12415501 NEURL 10p14 T C 0.11 10
rs10824026 SYNPO2L 10q22.2 G A 0.14 9
rs6490029 CUX2 12q24.11 A G 0.23 10
rs10507248 TBX5 12q24.21 G T 0.23 10
rs1152591 SYNE2 14q23.2 A G 0.45 9
rs7164883 HCN4 15q24.1 G A 0.09 9
rs2106261 ZFHX3 16q22.3 T C 0.16 9,12
Table 3.  The list of 17 AF top SNPs. It includes four independent SNPs at the PITX2 locus (with a number 
in parenthesis), and one top SNP at remaining 13 AF loci.
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The null hypothesis was that the interaction term, β int = 0. Each study estimated and provided β int and a robust 
estimate of standard error SE(β int) for each SNP interacting with each of the 17 AF-associated SNPs. Thus, we 
performed 17 interaction GWAS. The study-specific interaction regression parameter estimates r were then 
meta-analyzed using METAL32, applying a fixed effects approach weighted for the inverse of the variance. The 
effect of interaction was presented as an interaction odds ratio (OR), i.e., exp(βint). Given that we performed the 
genome-wide test for 17 SNPs, we defined significant interactions as those with a P-value less than 2.8 × 10−9  
(= 5 × 10−8/17 SNPs tested).
In the replication phase, we tested the association of significant or suggestive interactions (P < 5 × 10−7) in 
an independent cohort, UK Biobank. An interaction was replicated if it had the same direction of effect as the 
discovery, and the association P < 0.05/N, where N was the number of tests.
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